Top news of the week: 15.09.2020.
#COVID19 #futurefood #futureoffood #foodtech #plantbased #biotechnology #coronavirus
Career And Jobs
9 biopharma leaders pledge commitment to individual safety alongside “high ethical standards and sound scientific principles” in ongoing efforts to research and develop #COVID19 vaccines and treatments.
https://t.co/nqTDZaR07w
OpenBiopharma Leaders Unite to Stand with Science
The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (N
Phase III migraine flop sends a small-cap biotech player into a deadly tailspin
$STSA - 83%
https://t.co/clnvDZzHN6
OpenPhase III migraine flop sends a small-cap biotech player into a deadly tailspin
A small-cap player looking to cash in quickly on a reformulated drug just got flattened this morning as their one-trick pony got hit by a late-stage catastrophe. Bay Area-based Satsuma ...
Oncology biotech Prelude guns for $100M IPO
Fierce 15 winner Prelude Therapeutics is going for a $100 million IPO, a pretty common goal for biotechs in 2020, as it looks to finish off early clinical work for its cancer candidate ...
After Bind bankruptcy, Hirsch once again helms a biotech, landing at C4 https://t.co/X5UL8BwhaB https://t.co/FhXX9A25Oq
OpenAfter Bind bankruptcy, Hirsch once again helms a biotech, landing at C4
When CEO and president at Bind Therapeutics, Andrew Hirsch had to swing the ax to his workforce, file for bankruptcy and in the end sell off its remaining assets to Pfizer.
Ginkgo will work with Totient, an antibody-focused startup that is just emerging from stealth mode today, to turn their alternate means of generating virus-neutralizing into a treatment that could potentially treat or temporarily prevent infection. https://t.co/4wpbLGIpTI
OpenExclusive: Ginkgo teams with unknown upstart in hunt for Covid-19 antibody
Ginkgo Bioworks, with its vast warehouses of automated robots and bioreactors, has played a behind-the-scenes role in the anti-Covid fight since the start of the pandemic. They've ...
Korro Bio has got off a meaty series A funding round, nabbing $91.5 million to run its platform of single-base RNA edits to treat a range of diseases. https://t.co/Uw1o1FmwtZ
OpenKorro Bio hits the high notes with $91.5M series A to run its OPERA RNA platform
Korro Bio has got off a meaty series A funding round, nabbing $91.5 million to run its platform of single-base RNA edits to treat a range of diseases.
.@motiffoodworks is leveraging the power of microbe engineering and fermentation to revolutionize the future of #plantbased foods. https://t.co/mBBPdQ6asP #foodtech #futurefood #futureoffood @Ginkgo
OpenCould Fermentation Power The Future Of Plant-Based Foods? Motif FoodWorks Thinks Yes.
Motif FoodWorks is leveraging the power of microbe engineering and fermentation to revolutionize the future of plant-based foods.
A real pandemic is an awful way to put #biotechnology to the test. But that’s exactly what is happening with #coronavirus. Here are the stories of three women putting synthetic biology to use in saving lives. https://t.co/7yesYhgBsd @sives54 @janiceschen @mammothbiosci @Ginkgo
OpenSynthetic Biology Versus Coronavirus: Three Women In A Cutting-Edge Field Using Biological Engineering To Save Lives
A real pandemic is an awful way to put biotechnology to the test. But that’s exactly what is happening with coronavirus. Here are the stories of three women putting synthetic biology to use ...